The Food and Drug Administration carried out an inspection of Safe Guard Biologicals, Inc. in King of Prussia on April 2, reviewing blood and blood products, based on information from the FDA’s website.
The final report found that Safe Guard Biologicals, Inc. was not required to take corrective measures regarding the organization’s operational practices.
The FDA regularly inspects facilities nationwide to confirm work environments and their products comply with FDA regulations designed to protect public health. The inspection results are publicly reported.
The FDA’s website states that it is a federal agency chiefly responsible for regulating the safety and quality of human and animal drugs, biological products, medical supplies and tobacco products.
Information for this article comes from the U.S. Food and Drug Administration. The original data is available here.
